Company Overview of aTyr Pharma, Inc.
Key Executives for aTyr Pharma, Inc.
|John D. Mendlein Ph.D., J.D.||83 Relationships||Chief Executive Officer and Director||56|
|Paul R. Schimmel Ph.D.||82 Relationships||Founder and Director||75|
|Xiang-Lei Yang Ph.D.||No Relationships||Founder||--|
|John T. Blake CPA||No Relationships||Senior Vice President of Finance||40|
|David J. King Ph.D.||No Relationships||Senior Vice President of Research||57|
|View More Key Executives|
aTyr Pharma, Inc. Board Members*
|Name||Board Relationships||Primary Company||Age|
|John K. Clarke||82 Relationships||Alnylam Pharmaceuticals, Inc.||62|
|John D. Mendlein Ph.D., J.D.||83 Relationships||aTyr Pharma, Inc.||56|
|Paul R. Schimmel Ph.D.||82 Relationships||aTyr Pharma, Inc.||75|
|James C. Blair Ph.D.||175 Relationships||Domain Associates, L.L.C.||76|
|Kathryn E. Falberg||71 Relationships||The Trade Desk, Inc.||55|
aTyr Pharma, Inc. Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|Audit Committee||Kathryn E. Falberg||71 Relationships||3 Executives|
|Compensation Committee Ph.D.||James C. Blair||175 Relationships||3 Executives|
|Nominating Committee||John K. Clarke||82 Relationships||3 Executives|
|Corporate Governance Committee||John K. Clarke||82 Relationships||3 Executives|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
|Total Short Term Compensation|
|Total Value of Options||$494.7K|
INDUSTRY EXECUTIVE CHANGES
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.